Summary

Other Scenarios:

Buyer: sanofi-aventis (ADR) (SNY) Last Price: 43.98 Market Cap.: 119.58B
Target: New River Pharmaceuticals, Inc. (NRPH) Last Price: 63.73 Market Cap.: 2.36B

Lines of Business Summary:

Product Summary:

Overlap & Complementary Sectors

Sector Buyer Target # of Focused Companies
*Healthcare 867
Biopharmaceuticals 330
Medical Devices   244
Veterinary Products and Services   6

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Sample Products in Similar Lines of Business

Sample Products in Complementary Lines of Business
Buyer (Total: 247)
  • Allegra (Fexofenadine Hydrochloride)
  • AVE0675 (Toll-Like Receptor Agonist)
  • SAR 389644 (Prostaglandin D2 Antagonist)
  • Xyzal (Levocetirizine Dihydrochloride)
Target (Total: 5)
  • NRP409
  • Vyvanse (Lisdexamfetamine Dimesylate)/Formerly NRP104
  • NRP290 (Hydrocodone Prodrug)
  • NRP388
Buyer
  • Rapidpoint ENOX Test
  • Tubersol (Tuberculin Purified Protein Derivative)
  • OptiClik
  • Hyalgan (Sodium Hyaluronate)
Target

n/a

Business Relationship Summary:

Top Key Suppliers

Top Key Customers
Buyer (Total: 44)
  • IDM Pharma Inc. (IDMI)
  • Regeneron Pharmaceuticals, Inc. (REGN)
  • Cell Genesys, Inc. (CEGE)
  • Dendrite International, Inc. (DRTE)
Target (Total: 1)
  • Albany Molecular Research, Inc. (AMRI)
Buyer (Total: 10)
  • Roche Holding Ltd. (ADR) (RHHBY)
  • Bristol Myers Squibb Co. (BMY)
  • Alcon, Inc. (ACL)
  • Cephalon, Inc. (CEPH)
Target (Total: 0)

n/a

Key Financial Summary:

Key Metrics

  Buyer Target
Number of Employees 100,289 38
Revenue Per Employee 407,548.4 248,982.3
Total Revenue 10,141.7 2.5
Total Expenses 14,212.4 50.1
Other Revenue 304.9 0.0
Cost of Revenue 2,659.8 0.0
SG&A Expense 2,879.1 29.3
Research & Development 1,619.4 16.6
Other Operating Expense 1,477.7 0.0
Operating Income -4,070.6 -47.7
Unusual Income 366.4 4.3
LT Debt to Capital 8.98 -0
Fwd P/E 12.94 -77.72
Fwd P/Rev 3.18 27.92
Book Value 60,978.9 -109.7
Curr Portion of LTD/Cap Lease 3,269.6 137.8

Individual Company Summary

Focused

Buyer

Focused (): *Healthcare > Biopharmaceuticals

Target

Focused (): *Healthcare > Biopharmaceuticals > Neurology

Business Description

Buyer

Sanofi-Aventis is a pharmaceutical group engaged in the research, development, manufacture and marketing of healthcare products. Its business includes two main activities: pharmaceuticals and human vaccines. In pharmaceutical activity, Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system and internal medicine. In the human vaccines activity, it offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines and travel vaccines. As of April 4, 2007, Sanofi-Aventis announced that Acomplia has been approved by Swissmedic, the Swiss Agency for therapeutics products, in association with a light hypocaloric diet and physical activity for obese patients or for overweight patients with at least one associated cardiovascular risk factor, after insufficient weight reduction following physical activity or alimentary adaptation.

Target

New River Pharmaceuticals Inc. is a specialty pharmaceutical company developing pharmaceuticals. Utilizing the Company's Carrierwave technology, it is developing molecular entities that are derivatives of public domain actives, and attempting to address certain deficiencies associated with drugs on the market. The Company?s drug development pipeline includes three active programs in clinical or preclinical development stages. All of its drug candidates are small molecules designed for oral delivery. Vyvanse is intended to provide a safer, abuse-resistant and effective alternative to existing amphetamine-based therapies used to treat Attention Deficit Hyperactiviy Disorder (ADHD). The Company is developing NRP290 to treat acute pain as an alternative to Lortab, Vicodin and Vicoprofen. NRP290 is intended to provide a safer, abuse-resistant and an effective alternative to opioids.

Deal Summary

Key Ratios

  Buyer Target
Gross Margin % 74.27 100
Operating Margin % 16.37 -174.85
Quick Ratio 0.11 0.88
Current Ratio 1.18 0.89
Coverage Ratio -0.02 -0.06
Total Assets 103,989.0 151.5
Return on Equity % 8.66 n/a
Return on Assets % 5.08 -37.43
Cash+ ST Inv. Per Share 0.57 3.98
Total Debt 9,285.9 137.8
Total Debt to Equity % 15.23 0
Total Debt to Tangible Equity % n/a n/a
Debt to Asset % 8.93 90.92

Product Summary

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
  
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
  
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
  
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
  
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
  
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
  
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
  
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
  
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
  
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
  
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
  
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
  
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
  
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
  
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
  
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
  
Medical Devices  
Clinical Diagnostics
The Clinical Diagnostics Subsector includes medical devices that analyze human body specimens within a medical setting. These devices, including equipment, biological and chemical reagents are primarily used for the diagnosis of diseases.
  
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
  
Orthopedics
The Orthopedics Subsector includes medical devices that diagnose and treat musculoskeletal diseases involving muscles, bones and joints.
  
Plastic/Reconstructive Surgery
The Plastic/Reconstructive Surgery Subsector includes medical devices that treat and modify a patient's external appearance.
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Product Details

Sector Buyer Target
*Healthcare
Biopharmaceuticals
Allergies  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for treatment of allergic reactions in early stages of clinical research where human subject is involved.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • AVE0675 (Toll-Like Receptor Agonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of allergic reactions in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 389644 (Prostaglandin D2 Antagonist)
  
Upper Respiratory  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • Xyzal (Levocetirizine Dihydrochloride)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.

Buyer Products:

  • Allegra-D (Fexofenadine/Pseudoephedrine)
  • Allegra-D 24 Extended-Release (Fexofenadine HCl/Pseudoephedrine HCl)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation using a steroidal compound.

Buyer Products:

  • Nasacort AQ Nasal Spray (Triamcinolone Acetonide)
  • Nasacort Nasal Inhaler (Triamcinolone Acetonide)
  • Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol
  
Cardiovascular System  
Heart Disorders  
Acute Coronary Syndrome (ACS)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat angina by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Angina  
Anticoagulating Agents  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Kerlone (Betaxolol Hydrochloride)
  
Arrhythmia  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Sectral (Acebutolol Chlohydrate)
  
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Cardizem Injectable (Diltiazem Hydrochloride)
  
Sodium Channel Blocking Agents/Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium and potassium into heart muscle cells.

Buyer Products:

  • Cordarone (Amiodarone Hydrochloride)
  • Multaq (Dronedarone)
  
Heart Failure (HF)  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.

Buyer Products:

  • Delix/Tritace (Ramipril)
  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that treat the excessive accumulation of fluids by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Inotropic/Vasodilatory Agents
Therapeutics that treat acute heart failure by increasing intracellular ionized calcium and contractile force in cardiac muscle and relaxing vascular muscle.

Buyer Products:

  • Primacor (Milrinone Lactate)
  
Myocardial Infarction (MI)  
Anticoagulating Agents  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • XRP0673 (Otamixaban)
  • HMR1069 (Guanylate Cyclase Activator)
  • AVE9488 (e-NOS Transcription Enhancer)
  • Ataciguat/HMR1766 (Guanylate Cyclase Activator)
  • AVE3247 (Factor X Inhibitor)
  • AVE5026 (Indirect Xa/IIa Inhibitor)
  • AVE3085 (e-NOS Transcription Enhancer)
  • AVE1231 (Potassium Channel Blocking Agent)
  • AVE-7688 (Ilepatril)
  • SSR 149744 (Celivarone)
  • SR 123781 (Hexadecasaccharide)
  • SL 65.0472 (Serotonin Receptor Antagonist)
  • XRP0038 (Plasmid Based Gene Therapy)
  • AVE0657 (NHE-3 Inhibitor)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of heart and circulatory system disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SSR 128428 (Hexadecasaccharide/Indirect Xa/IIa Inhibitior)
  • SAR 114646 (Antiarrhythmic Agent)
  • SSR 128429 (Indirect Xa/IIa IInhibitor)
  • SAR 377142 (Oral Factor X Inhibitor)
  • SAR 407899 (Rho Kinase Inhibitor)
  
Vascular Disorders  
Atherosclerosis  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that treat the narrowing or hardening of the arteries by inhibiting the action of adenosine diphosphate (ADP), which in turn inhibits the aggregation of platelets.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that prevent or treat clots in blood vessels by preventing blood clots from forming.

Buyer Products:

  • Lovenox (Enoxaparin Sodium)
  • Biotinylated Idraparinux
  • Idraparinux
  
Hypertension  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.

Buyer Products:

  • Delix/Tritace (Ramipril)
  
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.

Buyer Products:

  • Teczem (Enalapril/Diltiazem)
  
Angiotensin II Receptor Antagonists
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Angiotensin II Receptor Antagonists/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the angiotensin II receptor and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Avalide (Irbesartan/Hydrochlorothiazide)
  
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.

Buyer Products:

  • Sectral (Acebutolol Chlohydrate)
  • Kerlone (Betaxolol Hydrochloride)
  
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.

Buyer Products:

  • Cardizem SR (Diltiazem Hydrochloride)
  
Loop Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Hypovolemia  
Plasma Volumizers  
Albumin-Based
Therapeutics based on plasma proteins that treat a decrease in circulating fluid (plasma) in the body by increasing plasma volume.

Buyer Products:

  • Albuminar (Human Albumin)
  
Peripheral Vascular Disease  
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.

Buyer Products:

  • Trental (Pentoxifylline)
  
Stroke  
Anticoagulating Agents (Anticoagulants)  
Platelet Aggregation Inhibitors  
Adenosine Diphosphate (ADP) Inhibitors
Therapeutics that prevent or treat damage to nerve cells of the brain by preventing platelets from clumping together.

Buyer Products:

  • Plavix (Clopidogrel Bisulfate)
  
Thromboembolism  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat the obstruction of a blood vessel by preventing blood clots from forming.

Buyer Products:

  • Idraparinux
  • Lovenox (Enoxaparin Sodium)
  • Biotinylated Idraparinux
  
Dermatology  
Acne  
Rosacea  
Emollients
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by moisturizing and softening the skin.

Buyer Products:

  • Dermik Laboratories Noritate (Metronidazole)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat chronic inflammatory disorder of the face characterized by redness and pimple formation by inhibiting bacterial folic acid synthesis.

Buyer Products:

  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Vulgaris  
Antibacterial Agents  
Lincosamides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting bacterial protein synthesis.

Buyer Products:

  • Dermik Laboratories BenzaClin (Clindamycin/Benzoyl Peroxide)
  
Macrolides
Therapeutics that treat acne vulgaris caused by bacterial infection by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Dermik Laboratories Benzamycin (Erythromycin/Benzoyl Peroxide)
  
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.

Buyer Products:

  • Dermik Laboratories Benzagel (Benzoyl Peroxide)
  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Dermik Laboratories Klaron (Sodium Sulfacetamide)
  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Lesion/Scaling Disorders  
Actinic Keratoses  
Antimetabolite Agents  
Pyrimidine Analogs
Therapeutics that treat actinic keratoses by blocking the synthesis of DNA.

Buyer Products:

  • Dermik Laboratories Carac (5-Fluorouracil)
  
Chronic Urticaria  
Antihistamines
Therapeutics that treat allergic skin conditions by blocking the action of histamines.

Buyer Products:

  • Xyzal (Levocetirizine Dihydrochloride)
  • Allegra (Fexofenadine Hydrochloride)
  
Dermatitis  
Atopic (Eczema)  
Emollients
Topical therapeutics that soothe and soften the skin.

Buyer Products:

  • Dermik Laboratories Noritate (Metronidazole)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Seborrheic (Dandruff)  
Para Aminobenzoic Acid (PABA) Inhibitors
Therapeutics that treat bacterial infections of the skin by inhibiting a bacterial enzyme responsible for synthesis of folic acid.

Buyer Products:

  • Dermik Laboratories Sulfacet R (Sodium Sulfacetamide/Sulfur)
  
Dermatoses  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Dermatop Emollient Cream (Prednicarbate)
  • Dermik Laboratories Psorcon E (Diflorasone Acetate)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of skin disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • DL6063 (Topical Clindamycin Analogue/BPO)
  
Digestive System  
Gastrointestinal Tract Disorders  
Gastroesophageal Disorders  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.

Buyer Products:

  • Anzemet (Dolasetron Mesylate)
  
Liver Disorders  
Cirrhosis  
Complications  
Edema  
Loop Diuretic Agents
Therapeutics that prevent edema by excretion of sodium, potassium, chloride ions, and water in urine.

Buyer Products:

  • Lasix (Furosemide)
  
Vasopressin Antagonists
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by decreasing water reabsorption through the reduction in cellular permeability of the collecting ducts, resulting in an increase in urine volume and decreased osmolality.

Buyer Products:

  • SR 121463 (Satavaptan)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 140333 (Nolpitantium Besilate)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of digestive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SSR 241586 (NK3/NK2 Antagonist)
  
Endocrinology/Metabolism
Diabetes  
Induced Complications  
Central Diabetes Insipidus  
Antidiuretic Agents
Therapeutics that treat prevent the lose of water in the urine.

Buyer Products:

  • DDAVP (Desmopressin Acetate)
  
Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Insulin Dependent Diabetes Mellitus (IDDM)/Type 1 Diabetes  
Insulin Therapy  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Human Insulin
  • Lantus (Insulin Glargine)
  • Apidra (Insulin Glulisine [rDNA origin] Injection)
  
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes  
Cannabinoid Receptor Antagonists
Therapeutics that treat non-insulin dependent diabetes by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.

Buyer Products:

  • DiaBeta (Glyburide)
  • Amaryl (Glimepiride)
  
Insulin Therapy  
Recombinant Human
Therapeutics that are derived from human genes.

Buyer Products:

  • Apidra (Insulin Glulisine [rDNA origin] Injection)
  • Human Insulin
  • Lantus (Insulin Glargine)
  
Intermediary Metabolism Disorders  
Gout  
Hyperuricemia  
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.

Buyer Products:

  • Elitek (Rasburicase)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE5530 (Cholesterol Absorption Inhibitor)
  • AVE-0010 (Glucagons-Like Peptide-1 Receptor Agonist)
  • AVE0897 (PPAR Agonist)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE0847 (PPAR Agonist)
  • AVE2268 (SGLT2 Inhibitor)
  • AVE-7688 (Ilepatril)
  • AVE8134 (PPAR-Alpha Agonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR7226 (SGLT Inhibitor)
  • SAR 351034 (PPAR Agonist)
  • SAR 502250 (TPK1-GSK3 Beta Inhibitior)

Target Products:

  • NRP409
Hematology  
Hemophilia  
Hemophilia A  
Clotting Agents
Therapeutics that aid in blood coagulation.

Buyer Products:

  • Bioclate (Recombinant Antihemophilic Factor)
  • Helixate NexGen/FS (Recombinant Antihemophilic Factor)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE5530 (Cholesterol Absorption Inhibitor)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE8134 (PPAR-Alpha Agonist)
  • AVE0847 (PPAR Agonist)
  
Red Blood Cell (RBC) Disorders  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues by stimulating red blood cell production.

Buyer Products:

  • Dynepo (Erythropoietin)
  
Serum Factor Disorders  
Hyperuricemia  
Urate Oxidases
Therapeutics that reduce excess uric acid by catalyzing enzymatic oxidation of uric acid into an inactive and soluble metabolite.

Buyer Products:

  • Elitek (Rasburicase)
  
Hyponatremia  
Vasopressin Antagonists
Therapeutics that treat hyponatremia by decreasing water reabsorption through the reduction in cellular permeability of the collecting ducts, resulting in an increase in urine volume and decreased osmolality.

Buyer Products:

  • SR 121463 (Satavaptan)
  
Immunology  
Autoimmune Disorders  
Arthritis  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Arava (Leflunomide)
  
Multiple Sclerosis (MS)  
Immunomodulators
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths by altering the immune mechanisms.

Buyer Products:

  • Copaxone (Glatiramer Acetate)
  • HMR 1726 (Teriflunomide)
  
Psoriasis  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat a chronic autoimmune disease characterized by softening, separating, causing the shedding of the horny layer of the skin with a steroidal compound.

Buyer Products:

  • Dermik Laboratories Psorcon E (Diflorasone Diacetate)
  
Immune Deficiency Disorders  
Hereditary Angioedema  
Gonadotropin Inhibitors
Therapeutics that treat swelling under the skin caused by the absence of an essential immune regulator by increasing levels of C4 complement component.

Buyer Products:

  • Danocrine (Danazol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of immune disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE1701 (CCR1 Antagonist)
  • SR 140333 (Nolpitantium Besilate)
  • AVE9897 (CCR1 Antagonist)
  • SSR 150106 (Cytokine Inhibitor)
  
Infectious Diseases  
Bacterial  
Antibacterial Agents  
Broad Spectrum  
Antibiotics  
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Claforan (Cefotoxime Sodium)
  
Glycopeptides
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.

Buyer Products:

  • Targocid (Teicoplanin)
  
Ketolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.

Buyer Products:

  • Ketek (Telithromycin)
  
Narrow Spectrum  
Neurology  
Meningitis  
Antitubercular Agents
Therapeutics that treat inflammation of the lining of the brain and spinal cord by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Rifadin (Rifampin)
  
Respiratory System  
Respiratory Tract Infections  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the air passage involved in breathing, including the trachea, lungs and bronchi by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Zagam (Sparfloxacin)
  
Tuberculosis  
Antitubercular Agents
Therapeutics that treat a bacterial infection of the lung by inhibiting bacterial and mycobacterial RNA synthesis.

Buyer Products:

  • Priftin (Rifapentine)
  • Rifamate (Rifampin/Isoniazid)
  • Rifadin (Rifampin)
  • Rifater (Rifampin/Isoniazid/Pyrazinamide)
  
Urology  
Urinary Tract Infections (UTI)  
Antibacterial Agents (Antibiotics)  
Formaldehyde Precursors
Therapeutics that prevent bacterial infections of the urinary tract by forming formaldehyde, a compound that denatures bacterial proteins.

Buyer Products:

  • Hiprex (Methenamine Hippurate)
  
Quinolones/Fluoroquinolones
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by promoting breakage of bacterial DNA strands.

Buyer Products:

  • Neggram (Nalidixic Acid)
  
Vaccines  
Bacterial  
Combination  
Diphtheria/Tetanus (DT)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria and tetanus.

Buyer Products:

  • Imovax DT
  • DT Pediatric Adsorbed
  • Decavac (Tetanus and Diphtheria Toxoids Adsorbed for Adult Use)
  
Diphtheria/Tetanus/Acellular Pertussis (DTaP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and acellular pertussis.

Buyer Products:

  • Tripedia (DTaP)
  • Adacel
  
Diphtheria/Tetanus/Pertussis (DTP)
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause diphtheria, tetanus, and pertussis.

Buyer Products:

  • Daptacel
  • DPT Adsorbed
  
Single Target  
Meningitis
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause meningitis.

Buyer Products:

  • Menactra Toddler
  • Imovax Meningo A+C
  • Menactra Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
  • Menomune
  
Tetanus
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause tetanus.

Buyer Products:

  • Tet Tox Pl
  • Tetanus Toxoid
  
Typhoid Fever
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to pathogens that cause typhoid fever.

Buyer Products:

  • TYPHIM VI
  
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial or viral pathogen.

Buyer Products:

  • TriHIBit
  • Hexaxim (DTP-HepB-Polio-Hib Vaccine)
  • DT Polio
  • ActHIB
  • TetraCOQ
  • Pentacel
  • Imovax DPT Polio
  • Unifive (DTP-HepB-Hib Vaccine)
  
Mycological (Fungal)  
Antifungal Agents  
Narrow Spectrum  
Dermatology  
Onychomycosis (Nail)  
Azoles  
Triazoles
Therapeutics that treat fungal infections of the nail by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.

Buyer Products:

  • Dermik Laboratories Penlac (Ciclopirox)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 97193 (Ferroquine)
  • XRP2868 (Oral Streptogramins)
  • DTP-HepB-Polio-Hib Vaccine
  • Flu Pandemia
  • Dengue Vaccine
  • H7N1 Vaccine
  • CMV Vaccine
  • Meninge B
  • Meningococcal A,C,Y,W Infant
  • Pneumo
  • Flu Cell Vaccine
  
Protozoal  
Antiprotozoal Agents  
Narrow Spectrum  
Malaria  
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.

Buyer Products:

  • Aralen (Chloroquine Phosphate)
  • Plaquenil (Hydroxychloroquine Sulfate)
  • Primaquine Posphate
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of infectious diseases in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 21609 (TRL9 Agonist)
  • SAR 97276
  • SAR 116242
  • Rabies Vaccine
  • Malaria Vaccine
  • C. Trachomatis Vaccine
  • Yellow Fever Vaccine
  
Viral  
Vaccines  
Bacterial/Viral
Therapeutics that prevent or treat infectious disease by producing or artificially increasing immunity to a bacterial and viral pathogens.

Buyer Products:

  • Hexaxim (DTP-HepB-Polio-Hib Vaccine)
  • ActHIB
  • Pentacel
  • Imovax DPT Polio
  • Unifive (DTP-HepB-Hib Vaccine)
  • DT Polio
  • TriHIBit
  • TetraCOQ
  
Viral  
Combination  
Measles/Mumps/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles, mumps, and rubella.

Buyer Products:

  • Trimovax
  
Measles/Rubella
Therapeutics that prevent or treat viral infections by producing or artificially increasing immunity to measles and rubella. .

Buyer Products:

  • RUDI-ROUVAX
  
Single Target  
Influenza (Flu)
Therapeutics that prevent or treat viral infections of the respiratory tract by producing or artificially increasing immunity to the Influenza virus.

Buyer Products:

  • Avian Flu (H5N1) Vaccine
  • Flu Infants Vaccine
  • Fluzone (Influenza Virus Vaccine)
  
Japanese Encephalitis
Therapeutics that prevent or treat viral infections characterized by inflammation of the brain by producing or artificially increasing immunity to the Japanese B Encephalitis virus.

Buyer Products:

  • JE-VAX (Japanese Encephalitis Virus Vaccine)
  • ChimeriVax-JE
  
Measles
Therapeutics that prevent or treat viral infections characterized by a red rash by producing or artificially increasing immunity to the measles virus.

Buyer Products:

  • Imovax Sarampion
  
Papillomavirus
Therapeutics that prevent or treat viral infections characterized by the proliferation of epithelial cells, leading to the formation of warts and possibly other related diseases such as cervical pre-cancers and cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Polio
Therapeutics that prevent or treat viral infections that attack motor neurons of the brainstem and spinal cord by producing or artificially increasing immunity to the poliovirus

Buyer Products:

  • Imovax Polio
  • IPOL (Poliovirus Vaccination)
  
Rabies
Therapeutics that prevent or treat viral infections that infect brain cells by producing or artificially increasing immunity to the rabies virus.

Buyer Products:

  • Imogam Rabies HT
  • Imovax Rabies Vero
  
Rubella (German Measles)
Therapeutics that prevent or treat viral infections that begin in the lower respiratory tract and lead to a rash by producing or artificially increasing immunity to the rubella virus.

Buyer Products:

  • Imovax Rubeola
  
Yellow Fever
Therapeutics that prevent or treat viral infections characterized by fever and hemorrhage by producing or artificially increasing immunity to the yellow fever virus.

Buyer Products:

  • Stamaril/YF-Vax
  
Musculoskeletal System  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of skeletal system disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE9897 (CCR1 Antagonist)
  • SAR 479746/MLNM 0415 (Oral IKK-Beta Inhibitor)
  • AVE1701 (CCR1 Antagonist)
  • Icatibant (Bradykinin B2 Antagonist)
  
Skeletal Disorders  
Bone Disorders  
Osteoporosis  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.

Buyer Products:

  • Actonel (Risedronate Sodium)/Once Weekly Actonel/Actonel With Calcium
  
Paget`s Disease  
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.

Buyer Products:

  • Actonel (Risedronate Sodium)/Once Weekly Actonel/Actonel With Calcium
  • Skelid (Tiludronate Disodium)
  
Joint Disorders  
Rheumatoid Arthritis (RA)  
Disease Modifying Anti-Rheumatic Drugs (DMARD)  
Pyrimidine Synthesis Inhibitors
Therapeutics that alter or delay the rate of chronic joint inflammation by blocking the overproduction of immune cells.

Buyer Products:

  • Arava (Leflunomide)
  
Neurology
Neurological Disorders  
Alzheimer`s Disease  
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat Alzheimer's Disease by stimulating the serotonin receptors and the nerve growth factors.

Buyer Products:

  • Xaliproden
  
Epilepsy  
Partial Seizures  
Complex  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Primary Generalized Seizures  
Absence (Petit Mal)  
Adjunctive Therapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Monotherapy  
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.

Buyer Products:

  • Depakine (Valproate Sodium)
  
Neuromuscular Disorders  
Multiple Sclerosis (MS)  
Immunomodulators
Therapeutics that treat multiple sclerosis by changing the actions of the immune system.

Buyer Products:

  • Copaxone (Glatiramer Acetate)
  • HMR 1726 (Teriflunomide)
  
Myasthenia Gravis (MG)  
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.

Buyer Products:

  • Mytelase (Ambenonium Chloride)
  
Neuropathy  
Serotonin Receptor Agonists/Nerve Growth Factor (NGF) Agonists
Therapeutics that treat neuropathy by stimulating the serotonin receptors and the nerve growth factors.

Buyer Products:

  • Xaliproden
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • M100907 (Volinanserin)
  • SR 57667 (Paliroden)
  • SSR 180575 (PBR Ligand)
  • SSR 149415 (Vasopressin Antagonist)
  • AVE1625 (CB1 Receptor Antagonist)
  • AVE9897 (CCR1 Antagonist)
  • SSR 101010 (FAAH Inhibitor)
  • AVE8112 (PDE-4 Inhibitor)
  • AVE8488 (5HT-2A Antagonist)
  • SSR 180711 (Alpha7 Nicotinic Agonist)
  • SSR 411298 (FAAH Inhibitor)
  • SSR 125543 (CRF1 Antagonist)
  
Psychiatric Disorders
Childhood/Adolescent Disorders
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD)  
Sympathomimetic Agents
Therapeutic members of the amphetamine group of sympathomimetic amines that treat the disorder involving hyperactivity in children due to an abnormally short attention span.

Target Products:

  • Vyvanse (Lisdexamfetamine Dimesylate)/Formerly NRP104
  
Enuresis (Bedwetting)  
Antidiuretic Agents
Therapeutics that treat enuresis by suppressing the passing of urine.

Buyer Products:

  • DDAVP (Desmopressin Acetate)
  
Mood Disorders  
Depression  
Beta Adrenergic Receptor Agonists
Therapeutics that treat depression by stimulating neuronal activity in the prefontal cortex area of the brain.

Buyer Products:

  • SR 58611 (Amibegron)
  
Neurokinin-2 Receptor Antagonists
Therapeutics that treat depression by blocking the effects of NK-2, a neuropeptide that may modify serotonin and norepinephrine levels in the nervous system.

Buyer Products:

  • SR 48968 (Saredutant)
  
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.

Buyer Products:

  • Norpramin (Desipramine Hydrochloride)
  
Sleep Disorders  
Insomnia  
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.

Buyer Products:

  • Ambien CR (Zolpidem Extended Release)
  • Ambien (Zolpidem Tartrate)
  
Serotonin Receptor Antagonists
Therapeutics that treat insomnia by inhibiting the action of serotonin.

Buyer Products:

  • SR 147778 (Eplivanserin)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of nervous system and mental disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SSR 241586 (NK3/NK2 Antagonist)
  • SSR 102779 (NK-2 Antagonist)
  • SSR 126374 (CRF-1 Inhibitor)
  • SAR 110894 (H3 Antagonist)
  • SSR 103800 (GLTY-1 Inhibitor)
  • SAR 502250 (TPK1-GSK3 Beta Inhibitior)
  • SAR 501788 (PBR Ligand)
  
Obstetrics/Gynecology  
Female Genital Disorders  
Endometriosis  
Gonadotropin Inhibitors
Therapeutics that treat endometriosis by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danocrine (Danazol)
  
Fibrocystic Breast Disease  
Gonadotropin Inhibitors
Therapeutics that treat fibrocystic breast disease by preventing the release of the pituitary gland hormone, gonadotropin.

Buyer Products:

  • Danocrine (Danazol)
  
Infertility  
Hormonal Treatments  
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.

Buyer Products:

  • Clomid (Clomiphene Citrate)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 126768 (Oxytocin Receptor Anatgonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 150640 (Beta 3-Adrenoreceptor Agonist)
  
Oncology  
Breast Cancer  
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage breast cancers by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Metastatic  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  • XRP9881 (Larotaxel)
  
Digestive System  
Colon Cancer/Colorectal Cancer  
Localized  
Antimetabolite Agents
Therapeutics that treat and manage colorectal cancer by inhibiting the production of DNA.

Buyer Products:

  • Campto (Irinotecan)
  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage colorectal cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Gastric Cancer (Stomach Cancer)  
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the stomach by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Pyrimidine Analogs
Therapeutics that treat and manage cancers of the stomach by inhibiting the production of DNA.

Buyer Products:

  • S-1 (Tegafur/Gimeracil/Oteracil)
  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage stomach cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Pancreatic Cancer  
Metastatic  
Alkylating Agents  
Platinum-Based Agents
Platinum containing therapeutics that are meant to treat and manage pancreatic cancers that have spread beyond their original tumor site by interacting with DNA to inhibit cell division.

Buyer Products:

  • Eloxatin (Oxaliplatin)
  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the pancreas blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • XRP9881 (Larotaxel)
  
Head/Neck Cancer  
Localized  
Antimicrotubule Agents
Therapeutics that treat and manage primary tumors of the head and neck by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Hematology  
Leukemia (White Blood Cell Cancer)  
Lymphoid  
Acute  
Lymphoblastic  
Asparaginases
Therapeutics that treat and manage rapidly progressing cancers of immature lymphocytic cells by breaking down asparagine which is necessary for cell survival.

Buyer Products:

  • Oncaspar (Pegaspargase)
  
Chronic  
Lymphocytic (CLL)  
Cyclin-Dependent Kinase Inhibitors
Therapeutics that treat and manage slowly progressing cancers of lymphocytic cells by interferring with cyclin-dependent kinase which regulates cell cycle and division.

Buyer Products:

  • Alvocidib (Flavopiridol)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 244738 (Antitumoral Agent)
  • AVE1642 (Anti-IGF)
  • AVE8062 (Combretastatin Derivative)
  • AVE9633 (Monoclonal Antibody)
  • UVIDEM (Cell-Based Vaccine)
  • XRP6258 (Taxoid, Tubulin Inhibitor)
  • VEGF Trap (Vascular Endothelial Growth Factor Antagonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.

Buyer Products:

  • SAR 566658
  • SAR 412988 (Multiple Angiokinase Inhibitor)
  • SAR 103168 (Multikinase Inhibitor)
  • Colorectal Cancer Vaccine
  • SSR 250411 (Antimitotic Agent)
  • SSR 97225 (Antimitotic Agent)
  • SAR3419 (Tubulin Inhibitor)
  • SSR 106462/CEP 11981 (Antitumoral Agent)
  • Melanoma Vaccine
  
Respiratory System/Thoracic  
Lung Cancer  
Non Small Cell Lung Cancer (NSCLC)  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  
Hypoxic Cytotoxins
Therapeutics that treat lung cancer by targeting only cells with very low concentrations of oxygen.

Buyer Products:

  • Tirapazamine
  
Urology  
Cervical Cancer  
Localized  
Papillomavirus Vaccines
Therapeutics that are meant to promote an immune response against the Papillomavirus that are involved in the pathogenesis of cervical cancer.

Buyer Products:

  • Gardasil (Quadrivalent Human Papillomavirus Recombinant Vaccine)
  
Kidney Cancer (Renal Cell Carcinoma)  
Metastatic  
Vaccines
Therapeutics that are meant to treat and manage advanced and metastatic cancers of the kidneys by eliciting a specific immune response against the cancer cells.

Buyer Products:

  • Trovax (5T4 Tumor Antigen Cancer Vaccine)
  
Prostate Cancer  
Metastatic  
Androgen Receptor Blockers
Therapeutics that treat and manage prostate cancers that have spread beyond their original tumor site by binding to the androgen receptors in target tissue thus inhibiting the action of androgens.

Buyer Products:

  • Nilandron (Nilutamide)
  • Eligard (Leuprolide Acetate)
  
Antimicrotubule Agents
Therapeutics that treat and manage cancers of the prostate by blocking the normal function of microtubules, thus inhibiting cell division.

Buyer Products:

  • Taxotere (Docetaxel)
  • XRP6258 (Taxoid, Tubulin Inhibitor)
  
Urinary Bladder Cancer  
Papillocarcinoma  
Vaccines
Therapeutics that are meant to promote an immune response against a patient's bladder cancer.

Buyer Products:

  • TheraCys (BCG Live)
  
Transitional Cell Carcinoma  
Vaccines
Therapeutics that treat and mange cancers arising from the lining of the bladder by stimulating the bodies immune system to combat the cancer.

Buyer Products:

  • TheraCys (BCG Live)
  
Ophthalmology  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of eye disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • VEGF Trap (Vascular Endothelial Growth Factor Antagonist)
  
Pain Management
Narcotics  
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.

Buyer Products:

  • Talacen (Pentazocine Hydrochloride)
  • Talwin (Pentazocine And Naloxone Hydrochlorides)
  
Opioid Analgesics
Therapeutics that treat pain by providing the body with a milder opioid substitute.

Buyer Products:

  • Demerol (Meperidine Hydrochloride)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of pain in early stages of clinical research where human subject is involved.

Buyer Products:

  • SSR 240612 (Bradykinin B1 Antagonist)

Target Products:

  • NRP290 (Hydrocodone Prodrug)
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of pain in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 115740 (TRPV1 Antagonist)
  • SAR 407899 (Rho Kinase Inhibitor)

Target Products:

  • NRP388
  • NRP369 (Oxycodone Prodrug)
Respiratory System  
Lower Respiratory Tract Disorders (Lung Disorders)  
Asthma  
Acute Treatments  
Bronchodilators  
Alpha Adrenergic Receptor Agonists/Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.

Buyer Products:

  • Broncholate (Ephedrine HCl/Guaifenesin)
  
Prophylactic Treatments  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat asthma by reducing inflammation in the lung passages with steroids.

Buyer Products:

  • Alvesco (Ciclesonide)
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • Ketek (Telithromycin)
  • Allegra (Fexofenadine Hydrochloride)
  • AVE8923 (Tryptase B Inhibitor)
  • ALVESCO (Ciclesonide)/AVE2635 (Formoterol)
  • AVE0675 (Toll-Like Receptor Agonist)
  
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of respiratory disorders in very early stages of research where no human subject is involved.

Buyer Products:

  • SAR 21609 (TRL9 Agonist)
  • SSR 161421 (Adenosine 3 Antagonist)
  • SAR 398171
  • AVE8680 (IKK Inhibitor)
  • AVE0657 (NHE-3 Inhibitor)
  • SAR 389644 (Prostaglandin D2 Antagonist)
  
Upper Respiratory Tract Disorders  
Coughs/Colds  
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.

Buyer Products:

  • Allegra (Fexofenadine Hydrochloride)
  • Xyzal (Levocetirizine Dihydrochloride)
  
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.

Buyer Products:

  • Allegra-D (Fexofenadine/Pseudoephedrine)
  
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.

Buyer Products:

  • Zephrex/Zephrex LA (Pseudoephedrine HCI, Guaifenesin)
  
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress the inflammation in the upper respiratory tract with steroidal compounds.

Buyer Products:

  • Nasacort AQ Nasal Spray (Triamcinolone Acetonide)
  • Nasacort HFA (Triamcinolone Acetonide) Nasal Aerosol
  • Nasacort Nasal Inhaler (Triamcinolone Acetonide)
  
Surgery  
General  
Complications  
Nausea/Vomiting  
Serotonin Receptor Antagonists
Therapeutics that prevent or treat post surgical nausea and vomiting by blocking the receptors that bind serotonin, a neurotransmitter.

Buyer Products:

  • Anzemet (Dolasetron Mesylate)
  
Musculoskeletal System  
Deep Vein Thrombosis (DVT)  
Anticoagulating Agents (Anticoagulants)  
Thrombin Inhibitors
Therapeutics that treat vascular obstructions due to platelets and cell matter by blocking an enzyme involved in the clotting process.

Buyer Products:

  • Idraparinux
  • Lovenox (Enoxaparin Sodium)
  
Toxicology  
Animal Poisoning  
Scorpions  
Immunoglobulins
Therapeutics that treat scorpion bites with target specific proteins that neutralize the poison.

Buyer Products:

  • LABS 50
  
Snakes  
Immunoglobulins
Therapeutics that treat snake bites with target specific proteins that neutralize the poison.

Buyer Products:

  • ANTIREPT Pasteur
  • Pasteur IPSER Europe
  • Pasteur IPSER Africa
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of toxicity in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 14778 (Surinabant)
  
Substance Abuse  
Withdrawal  
Nicotine (Smoking Cessation)  
Cannabinoid Receptor Antagonists
Therapeutics that treat nicotine withdrawal by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.

Buyer Products:

  • SSR 591813 (Dianicline)
  • Nicorette (Nicotine Polacrilex Gum)
  • NicoDerm CQ (Nicotine Transdermal System)
  
Urology  
Male Genital Disorders  
Prostate  
Benign Prostate Hyperplasia (BPH)  
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.

Buyer Products:

  • Uroxatral/Xatral OD (Alfuzosin) Extended-Release
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • AVE-7688 (Ilepatril)
  • SSR 240600 (NK1 Antagonist)
  
Urological Disorders  
Kidney (Renal)  
Chronic Renal Failure (CRF)  
Complications  
Anemia  
Recombinant Human Erythropoietins
Therapeutics that treat the condition resulting from the scarcity of red blood cells by inducing the production of red blood cells.

Buyer Products:

  • Dynepo (Erythropoietin)
  
Edema  
Loop Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissues by promoting the excretion of urine.

Buyer Products:

  • Lasix (Furosemide)
  
Diabetic Nephropathy  
Angiotensin II Receptor Antagonists
Therapeutics that treat diabetes induced kidney disese by blocking the angiotensin II receptor.

Buyer Products:

  • Aprovel/Avapro (Irbesartan)
  
Weight Management  
Obesity  
Cannabinoid Receptor Antagonists
Therapeutics that suppress appetite by blocking endogenous cannabinoid binding to neuronal CB1 receptors.

Buyer Products:

  • Zimulti (Rimonabant)/Formerly Acomplia
  
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in early stages of clinical research where human subject is involved.

Buyer Products:

  • SR 14778 (Surinabant)
  • Antiobesics
  • AVE1625 (CB1 Receptor Antagonist)
  
Medical Devices  
Clinical Diagnostics  
Hemostasis/Coagulation  
Reagents  
Test Kits  
Specialty Assays
Test kits used to assay for special, esoteric coagulation factors..

Buyer Products:

  • Rapidpoint ENOX Test
  
Immunoassays  
Reagents  
Test Kits  
Bacterial  
Tuberculosis
Immunoassay test kits which quantitatively measure tuberculosis antibody in plasma or serum.

Buyer Products:

  • Tubersol (Tuberculin Purified Protein Derivative)
  
Drug Delivery  
Percutaneous (Subcutaneous/Intramuscular/Intravenous)  
Automatic Injectors
Pen-shaped medical devices used to contain and deliver liquid medications to a specified needle depth with a press of a button.

Buyer Products:

  • OptiClik
  
Orthopedics  
Treatment  
Pain Management  
Joint/Region Specific  
Knee  
Viscosupplementation
Devices used to mimic the synovial fluid in the knee joint in order to relieve pain associated with osteoarthritis.

Buyer Products:

  • Hyalgan (Sodium Hyaluronate)
  
Plastic/Reconstructive Surgery  
Surgical  
Procedure/Region Specific  
Implants  
Facial  
Injectable  
Polymer-Based
Injectable implants composed of polymers, or plastics.

Buyer Products:

  • Dermik Laboratories SCULPTRA (Injectable Poly-L-Lactic Acid)
  
Veterinary Products and Services  
Veterinary Pharmaceuticals
The Veterinary Pharmaceuticals Subsector includes companies that manufacture veterinary pharmaceuticals and vaccines for the prevention and treatment of veterinary diseases.

Buyer Products:

  • Merial Group Ltd.
  

- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.

- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.

- Sector Participation. Denotes that the company develops products in this line of business.

Relationship Details

Key Competitors

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  GlaxoSmithKline plc (ADR) n/a 161,058.996 15.12 15.20 3.51 3.60 15.27
Novartis AG (ADR) n/a 130,937.348 24.87 16.90 3.56 3.30 6.59
Abbott Laboratories n/a 87,986.029 51.25 20.29 3.91 3.87 n/a
Eli Lilly & Co. n/a 62,916.207 23.63 16.66 4.01 3.60 5.73
Nastech Pharmaceutical n/a 280.190 n/a -8.46 9.83 9.84 6.47
Buyer
  Pfizer Inc. n/a 182,865.248 9.46 11.75 3.78 3.81 7.00
GlaxoSmithKline plc (ADR) n/a 161,058.996 15.12 15.20 3.51 3.60 15.27
Roche Holding Ltd. (ADR) n/a 157,158.883 24.84 24.29 4.66 n/a 6.98
Target
  Johnson & Johnson n/a 178,185.093 16.12 15.74 3.34 3.00 16.76
GlaxoSmithKline plc (ADR) n/a 161,058.996 15.12 15.20 3.51 3.60 15.27
Novartis AG (ADR) n/a 130,937.348 24.87 16.90 3.56 3.30 6.59
Abbott Laboratories n/a 87,986.029 51.25 20.29 3.91 3.87 n/a
Tyco International Ltd. n/a 63,567.884 16.04 16.08 1.52 1.46 11.09
Eli Lilly & Co. n/a 62,916.207 23.63 16.66 4.01 3.60 5.73
Shire plc (ADR) n/a 10,722.895 38.54 30.08 5.97 4.86 11.38
Endo Pharmaceuticals n/a 4,079.028 29.59 18.17 4.48 3.93 5.22
Watson Pharmaceuticals, Inc. n/a 2,734.972 n/a 21.87 1.38 1.07 257.36
Ligand Pharmaceuticals Inc. n/a 751.502 n/a -37.20 5.33 27.49 n/a
Noven Pharmaceuticals, Inc. n/a 591.006 36.97 21.12 9.74 7.12 3.39
Pain Therapeutics, Inc. n/a 356.877 57.67 161.00 6.62 5.98 4.58
Nastech Pharmaceutical n/a 280.190 n/a -8.46 9.83 9.84 6.47
Acura Pharmaceuticals, Inc. n/a 256.652 n/a n/a n/a n/a n/a
Amarin Corporation plc (ADR) n/a 225.804 n/a -8.59 448.00 n/a 7.82
UCB S.A. n/a n/a n/a n/a n/a n/a n/a
Purdue Pharma L.P. n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Dependent Suppliers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Albany Molecular Research, Inc. n/a 314.068 143.99 32.03 1.75 1.63 1.12
Buyer
  IDM Pharma Inc. 80.00% 91.529 n/a n/a 7.80 n/a 11.40
Regeneron Pharmaceuticals, Inc. 75.40% 1,533.134 n/a -13.12 24.16 22.59 7.08
Cell Genesys, Inc. 43.60% 338.023 n/a -2.91 247.93 14.28 7.77
Dendrite International, Inc. 10.00% 686.456 n/a 224.00 1.62 1.63 n/a
Vical Incorporated 1.05% 191.302 n/a -5.37 12.98 18.16 1.76
The Procter & Gamble Company n/a 198,789.202 20.81 20.79 2.70 2.61 n/a
Pfizer Inc. n/a 182,865.248 9.46 11.75 3.78 3.81 7.00
Teva Pharmaceutical Industries Ltd (ADR) n/a 22,436.579 41.09 17.88 2.67 2.49 20.09
Publicis Groupe S.A. (ADR) n/a 8,583.081 14.27 19.23 1.49 1.51 n/a
Liberty Property Trust n/a 4,555.515 17.09 15.67 6.83 6.40 2.43
Beckman Coulter, Inc. n/a 4,107.570 21.98 19.79 1.62 1.49 48.78
Millennium Pharmaceuticals, Inc. n/a 3,706.730 n/a -193.00 7.61 7.93 6.20
Brandywine Realty Trust n/a 2,937.975 1,181.84 12.75 4.43 4.20 1.82
Havas (ADR) n/a 2,384.614 38.88 n/a 1.21 n/a n/a
Washington Group International, Inc. n/a 1,873.941 23.18 22.24 0.55 n/a 2.67
MicroStrategy Incorporated n/a 1,575.406 22.23 20.48 5.02 4.49 12.00
Crucell N.V. (ADR) n/a 1,529.609 n/a -135.42 14.99 5.23 4.01
Lexington Realty Trust n/a 1,509.287 n/a 12.01 7.28 3.87 2.31
Human Genome Sciences n/a 1,477.738 n/a -6.44 57.37 37.01 6.91
Progress Software Corporation n/a 1,285.760 39.89 21.13 2.81 2.70 5.95
Nektar Therapeutics n/a 1,241.174 n/a -10.95 5.70 5.64 8.56
inVentiv Health Inc. n/a 1,151.496 22.47 23.30 1.50 1.27 n/a
Aspen Technology, Inc. n/a 1,147.759 55.70 23.36 3.62 3.50 15.38
Target
  Albany Molecular Research, Inc. n/a 314.068 143.99 32.03 1.75 1.63 1.12

- Defined by the Company - Defined by Others

Key Customers

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Buyer
  Roche Holding Ltd. (ADR) n/a 157,158.883 24.84 24.29 4.66 n/a 6.98
Bristol Myers Squibb Co. n/a 54,747.562 34.54 22.08 3.06 2.85 16.54
Alcon, Inc. n/a 41,566.179 30.83 26.85 8.49 7.69 18.35
Cephalon, Inc. n/a 4,983.348 34.41 20.73 2.82 2.84 101.17
King Pharmaceuticals, Inc. n/a 4,861.564 16.82 12.34 2.44 2.44 3.69
Medicis Pharmaceutical Corporation n/a 1,724.238 n/a 27.20 4.94 3.79 6.22
Regeneron Pharmaceuticals, Inc. n/a 1,533.134 n/a -13.12 24.16 22.59 7.08
Grupo Casa Saba, S.A. (ADR) n/a 881.989 12.42 n/a 0.42 n/a 2.00
Introgen Therapeutics, Inc n/a 179.605 n/a -5.63 156.11 35.92 4.85
VaxGen, Inc. n/a 59.592 n/a -0.54 1.90 2.46 0.77

- Defined by the Company - Defined by Others

Key Partners

  Name Dir Percent Market Cap. P/E Ratio (TTM) Fwd P/E P/R Ratio (TTM) Fwd P/Rev Price To Tang. Book Value
Overlap
  Shire plc (ADR) n/a 10,722.895 38.54 30.08 5.97 4.86 11.38
Albany Molecular Research, Inc. n/a 314.068 143.99 32.03 1.75 1.63 1.12
Buyer
  The Procter & Gamble Company n/a 198,789.202 20.81 20.79 2.70 2.61 n/a
Pfizer Inc. n/a 182,865.248 9.46 11.75 3.78 3.81 7.00
TOTAL S.A. (ADR) n/a 161,021.526 10.32 10.15 0.89 1.02 3.30
Roche Holding Ltd. (ADR) n/a 157,158.883 24.84 24.29 4.66 n/a 6.98
Novartis AG (ADR) n/a 130,937.348 24.87 16.90 3.56 3.30 6.59
Merck & Co., Inc. n/a 98,820.891 22.29 17.32 4.37 4.45 6.51
Abbott Laboratories n/a 87,986.029 51.25 20.29 3.91 3.87 n/a
Bristol Myers Squibb Co. n/a 54,747.562 34.54 22.08 3.06 2.85 16.54
Alcon, Inc. n/a 41,566.179 30.83 26.85 8.49 7.69 18.35
Teva Pharmaceutical Industries Ltd (ADR) n/a 22,436.579 41.09 17.88 2.67 2.49 20.09
Akzo Nobel N.V. (ADR) n/a 22,122.858 13.37 19.18 1.21 1.40 4.87
Becton, Dickinson and Co. n/a 19,180.810 28.32 20.91 3.28 3.05 6.12
Allergan, Inc. n/a 17,268.277 n/a 26.28 5.64 4.85 64.94
Shire plc (ADR) n/a 10,722.895 38.54 30.08 5.97 4.86 11.38
MedImmune, Inc. n/a 8,649.251 177.62 48.51 6.77 6.02 7.47
Elan Corporation, plc (ADR) n/a 6,521.737 n/a -25.36 11.64 8.03 n/a
Sepracor Inc. n/a 5,408.677 29.31 20.80 4.52 3.72 59.10
Cephalon, Inc. n/a 4,983.348 34.41 20.73 2.82 2.84 101.17
King Pharmaceuticals, Inc. n/a 4,861.564 16.82 12.34 2.44 2.44 3.69
Target
  Shire plc (ADR) n/a 10,722.895 38.54 30.08 5.97 4.86 11.38
Albany Molecular Research, Inc. n/a 314.068 143.99 32.03 1.75 1.63 1.12
DepoMed, Inc. n/a 152.370 n/a -4.07 15.95 5.89 n/a
University Of California, San Francisco n/a n/a n/a n/a n/a n/a n/a

- Defined by the Company - Defined by Others

Financials

  Buyer Target Combined Entity
Income Statement
Operating Items
Revenue 37,942.0 34.3 37,976.3
Other Revenue 1,492.4 0.0 1,492.4
Total Revenue 39,434.3 34.3 39,468.7
Cost of Revenue 10,145.8 0.0 10,145.8
SG&A Expense 10,724.8 49.0 10,773.8
Depreciation & Amortization 5,346.3 0.2 5,346.5
Research & Development 5,924.0 41.0 5,965.0
Interest Expense 0.0 0.0 0.0
Other Operating Expense 470.7 0.0 470.7
Unusual Expense (Income) 366.4 4.3 370.7
Total Expenses 32,978.1 94.4 33,072.4
Operating Income 6,456.3 -60.0 6,396.2
Non Operating Items
Interest Expense (Inc.), Net Non-Oprtng -107.0 3.6 -103.3
Gain/Loss On Sale Of Assets 0.0 -0.0 -0.0
Other, Net 0.0 0.0 0.0
Income Before Taxes 6,349.3 -56.4 6,292.9
Income Taxes 1,069.8 0.3 1,070.1
Income After Taxes 5,279.5 -56.7 5,222.8
Minority Interest (IS) -525.5 0.0 -525.5
Equity in Affiliates 603.1 0.0 603.1
Net Income - Excl. Xord. Items 5,357.0 -56.7 5,300.3
Accounting Change 0.0 -0.7 -0.7
Net Income - Incl. Xord. Items 5,357.0 -57.4 5,299.6
Income Avail. to Common 5,357.0 -57.4 5,299.6
Share Items
Basic Avg. Shares Outstanding 2,696.4 37.0 2,733.4
Basic EPS - Excl. Xord. Items 1.99 n/a 1.94
Basic EPS - Incl. Xord. Items 1.99 n/a 1.94
Full Dilution Adjustment 0.0 0.0 0.0
Fully Diluted Shares Outstanding 2,696.4 37.0 2,733.4
F.D. EPS - Excl. Xord. Items 1.99 n/a 1.94
F.D. EPS - Incl. Xord. Items 1.99 n/a 1.94
Dividends Per Common Share 1.17 0.00 1.17
Balance Sheet
Assets
Cash and Equivalents 1,541.9 87.0 1,628.9
ST Investments 0.0 60.0 60.0
Accounts Receivable 0.0 0.2 0.2
Inventory 0.0 0.0 0.0
Prepayments and Advances 0.0 1.1 1.1
Other Current Assets 14,719.2 0.0 14,719.2
Current Assets 16,261.0 148.3 16,409.3
PPE 0.0 2.9 2.9
Accum D&A 0.0 -0.7 -0.7
PPE, Net 8,316.4 2.2 8,318.6
Goodwill & Intangibles 69,818.1 0.0 69,818.1
Other Assets 0.0 0.0 0.0
Other LT Assets 9,593.5 1.1 9,594.5
Total Assets 103,989.0 151.5 104,140.6
Liabilities
Accounts Payable 0.0 6.0 6.0
Payable/Accrued 10,474.7 0.0 10,474.7
Accrued Expenses 0.0 13.8 13.8
ST Debt 0.0 0.0 0.0
Curr Port of LTD & Cap Lease Oblg 3,269.6 137.8 3,407.4
Other (Current) Liabilities 0.0 9.6 9.6
Current Liab. 13,744.3 167.2 13,911.5
LT Debt 6,016.3 0.0 6,016.3
Capitalized Lease Obligations 0.0 0.0 0.0
Total LT Debt 6,016.3 0.0 6,016.3
Minority Interest (BS) 294.2 0.0 294.2
Deferred Taxes 12,364.3 0.0 12,364.3
Other LT Liab. 10,591.1 94.1 10,685.1
Total Liabilities 43,010.2 261.2 43,271.4
Shareholders Equity
Common Stock 0.0 0.0 0.0
Additional Paid in Capital 0.0 17.5 17.5
Retained Earnings 0.0 -127.3 -127.3
Other Equity 60,978.9 0.0 60,978.9
Total Equity 60,978.9 -109.7 60,869.2
Total Liab. & Equity 103,989.0 151.5 104,140.6
Shares Outstanding 2,718.9 37.0 2,755.8
Cash Flow
Operating Cash Flow
CF Net Income 5,357.0 -57.4 5,299.6
CF Depreciation 8,174.6 0.2 8,174.8
CF Deferred Taxes 0.0 0.0 0.0
Other Non-Cash Items -746.2 42.7 -703.5
Change in Working Capital -3,954.3 30.5 -3,923.8
Total Cash From Operating Activities 8,831.2 15.9 8,847.1
Investing Cash Flow (not calculated)
Capital Expenditures -1,944.4 -2.1 -1,946.4
Other Investing Cash Flows 887.9 -10.8 877.2
Total Cash From Investing Activities -1,056.4 -12.8 -1,069.2
Financing Cash Flow (not calculated)
Dividends Paid -2,730.7 0.0 -2,730.7
Purchase Or Sale of Stock 66.9 31.7 98.6
Purchase and Retirement of Debt -6,719.7 89.7 -6,630.0
Other Financing Cash Flow -10.7 -41.0 -51.7
Total Cash From Financing Activities -7,828.3 80.4 -7,747.9
Exchange Rate Effects -74.9 0.0 -74.9
Net Change in Cash -128.4 83.5 -44.9
Cash Interest Paid 0.0 0.0 0.0